In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.
在2型糖尿病中，SGLT-2 抑制劑對心血管和腎臟結果的影響與GLP-1 受體激動劑的使用無關。
Ann Intern Med 2024-11-04
Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
鈉葡萄糖共同轉運蛋白-2抑制劑和二肽基胺肽酶-4抑制劑聯合治療對心血管和腎臟結果的影響：隨機心血管結果試驗的荟萃分析。
Endocr Pract 2023-07-18
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
預測 SGLT-2 抑制劑與 GLP-1 受體激動劑對第二型糖尿病主要不良心血管事件的療效特徵：一項荟萃分析研究。
Cardiovasc Diabetol 2023-07-13
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
GLP-1 受體激動劑治療在第2型糖尿病患者中的應用：單獨使用及與 SGLT2 抑制劑合併治療。
J Am Coll Cardiol 2023-08-04
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.
第二型糖尿病患者合併輕至中度慢性腎臟疾病時，鈉葡萄糖共同轉運蛋白2抑制劑與葡萄糖樣肽-1受體激動劑的比較效果。
Diabetes Obes Metab 2024-03-14
Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
二型糖尿病患者合併使用鈉葡萄糖轉運蛋白2抑制劑和葡萄糖樣肽-1受體激動劑的效果和安全性：觀察性研究的系統性回顧和荟萃分析。
Cardiovasc Diabetol 2024-03-21
Efficacy and Safety of the Combination or Monotherapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: An update Systematic Review and Meta-analysis.
GLP-1受體激動劑和SGLT-2抑制劑在2型糖尿病中的聯合或單獨治療的功效和安全性：最新系統性回顧和荟萃分析。
Am J Med Sci 2024-07-08
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
SGLT2抑制劑單獨或聯合GLP-1受體激動劑的療效和安全性：一項隨機對照試驗的SMART-C合作性荟萃分析。
Lancet Diabetes Endocrinol 2024-07-11
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
SGLT2 抑制劑與 GLP-1 受體激動劑在 2 型糖尿病中的腎臟與心血管效果比較。
J Am Coll Cardiol 2024-08-14
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
GLP-1 受體激動劑單獨及與 SGLT2 抑制劑聯合使用在 2 型糖尿病中的心血管、腎臟及安全性結果：系統性回顧與統合分析。
Circulation 2024-08-30
Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions.
結合 GLP-1 受體激動劑和 SGLT-2 抑制劑以預防 2 型糖尿病的心血管疾病：一項包含多重網絡元回歸的系統性回顧。
World J Diabetes 2024-11-04